Agatha, a DX Service for Clinical Trials, Surpasses 80,000 Global Users
Agatha Inc. announced that its clinical trial document management cloud system 'Agatha' has reached over 80,000 global users. It holds a significant market share in Japan, used by 76% of medical institutions and 96% of pharmaceutical companies.
📋 Article Processing Timeline
- 📰 Published: April 28, 2026 at 19:00
- 🔍 Collected: April 28, 2026 at 10:31
- 🤖 AI Analyzed: April 28, 2026 at 14:31 (3h 59m after Collected)
Agatha Inc. (Headquarters: Chuo-ku, Tokyo; Representative Director and President: Chiemi Kamakura; hereinafter "the Company") is pleased to announce that its clinical trial document management cloud system, "Agatha," has surpassed 80,000 global users. Currently, "Agatha" is used by approximately 76% (*1) of medical institutions conducting clinical trials in Japan and approximately 96% (*2) of pharmaceutical companies.
(*1) Based on the Company's research as of April 2026. Calculated based on 1,520 medical institutions implementing Agatha, including indirect use.
(*2) Based on the Company's research as of April 2026. Calculated based on 103 PMDA applicant companies (corporate clinical trials only, excluding investigator-initiated trials) including indirect use.
■ Background of the Rapid Increase in Users and Facilities
"Agatha" is being introduced in many domestic medical institutions, pharmaceutical companies, medical device companies, CROs, SMOs, clinical laboratories, etc., as a cloud service that streamlines the sharing and management of clinical trial-related documents between medical institutions and pharmaceutical companies.
By centralizing the exchange and management of clinical trial documents, which were previously conducted mainly via paper and email, on the cloud, we have achieved both operational efficiency and quality improvement.
In recent years, with the increasing need for digitalization and efficiency in clinical trial operations, it has been evaluated as a platform for achieving smooth information collaboration between stakeholders, and its use is expanding in both medical institutions and pharmaceutical companies.
■ Comment from Chiemi Kamakura, Representative Director and President of Agatha Inc.
"I am very pleased that the number of global users of 'Agatha' has surpassed 80,000 and that the number of medical institutions using it in Japan has exceeded 1,500. I would like to express my sincere gratitude to all the medical institutions and pharmaceutical companies that use our service daily.
'Agatha' has evolved together with the front-line staff as a foundation for connecting many stakeholders involved in clinical trials and supporting the efficiency of document management and sharing. I believe that such efforts have led to the current expansion of use.
We will continue to work on further increasing the value of our services to contribute to the realization of a society where better treatments can be delivered to patients as soon as possible through the efficiency of clinical trials and research."
[About Agatha Inc.]
Agatha Inc. started with a vision to contribute to the improvement of quality, speed, and efficiency of clinical trials, clinical research, and manufacturing by providing "Agatha," a cloud service for sharing, managing, and storing clinical trial/quality-related documents, to medical institutions, pharmaceutical companies, medical device companies, CROs, SMOs, clinical laboratories, and more.
Our mission is to create a mechanism and foundation for creating new treatments and drugs using the latest technology, to contribute to the healthy lives of people around the world, and to contribute to creating an environment where future children around the world can access rich lifestyles, culture, technology, and medical care.
[Company Overview]
Company Name: Agatha Inc.
Representative: Representative Director and President Chiemi Kamakura
Address: Kabuto One 9F WeWork, 7-1 Nihonbashi Kabuto-cho, Chuo-ku, Tokyo 103-0026, Japan
URL: https://www.agathalife.com/
Established: October 2, 2015
(*1) Based on the Company's research as of April 2026. Calculated based on 1,520 medical institutions implementing Agatha, including indirect use.
(*2) Based on the Company's research as of April 2026. Calculated based on 103 PMDA applicant companies (corporate clinical trials only, excluding investigator-initiated trials) including indirect use.
■ Background of the Rapid Increase in Users and Facilities
"Agatha" is being introduced in many domestic medical institutions, pharmaceutical companies, medical device companies, CROs, SMOs, clinical laboratories, etc., as a cloud service that streamlines the sharing and management of clinical trial-related documents between medical institutions and pharmaceutical companies.
By centralizing the exchange and management of clinical trial documents, which were previously conducted mainly via paper and email, on the cloud, we have achieved both operational efficiency and quality improvement.
In recent years, with the increasing need for digitalization and efficiency in clinical trial operations, it has been evaluated as a platform for achieving smooth information collaboration between stakeholders, and its use is expanding in both medical institutions and pharmaceutical companies.
■ Comment from Chiemi Kamakura, Representative Director and President of Agatha Inc.
"I am very pleased that the number of global users of 'Agatha' has surpassed 80,000 and that the number of medical institutions using it in Japan has exceeded 1,500. I would like to express my sincere gratitude to all the medical institutions and pharmaceutical companies that use our service daily.
'Agatha' has evolved together with the front-line staff as a foundation for connecting many stakeholders involved in clinical trials and supporting the efficiency of document management and sharing. I believe that such efforts have led to the current expansion of use.
We will continue to work on further increasing the value of our services to contribute to the realization of a society where better treatments can be delivered to patients as soon as possible through the efficiency of clinical trials and research."
[About Agatha Inc.]
Agatha Inc. started with a vision to contribute to the improvement of quality, speed, and efficiency of clinical trials, clinical research, and manufacturing by providing "Agatha," a cloud service for sharing, managing, and storing clinical trial/quality-related documents, to medical institutions, pharmaceutical companies, medical device companies, CROs, SMOs, clinical laboratories, and more.
Our mission is to create a mechanism and foundation for creating new treatments and drugs using the latest technology, to contribute to the healthy lives of people around the world, and to contribute to creating an environment where future children around the world can access rich lifestyles, culture, technology, and medical care.
[Company Overview]
Company Name: Agatha Inc.
Representative: Representative Director and President Chiemi Kamakura
Address: Kabuto One 9F WeWork, 7-1 Nihonbashi Kabuto-cho, Chuo-ku, Tokyo 103-0026, Japan
URL: https://www.agathalife.com/
Established: October 2, 2015